| 1 | 17545310 | 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. | J Pharmacol Exp Ther | 2007 Sep |
1 |
| 2 | 20660124 | Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function. | J Pharmacol Exp Ther | 2010 Oct |
3 |
| 3 | 22362844 | Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. | Eur Respir J | 2012 Oct |
1 |
| 4 | 22918043 | Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery. | J Pharmacol Exp Ther | 2012 Dec |
1 |
| 5 | 24392948 | Selexipag for the treatment of pulmonary arterial hypertension. | Expert Opin Pharmacother | 2014 Feb |
1 |
| 6 | 25277144 | Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects. | Pharmacology | 2014 |
1 |
| 7 | 25850750 | Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag. | Am J Cardiovasc Drugs | 2015 Jun |
1 |
| 8 | 25851691 | Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects. | Br J Clin Pharmacol | 2015 Oct |
1 |
| 9 | 26152132 | Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study. | Int J Clin Pharmacol Ther | 2015 Sep |
2 |
| 10 | 26291199 | Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension. | J Med Chem | 2015 Sep 24 |
1 |
| 11 | 26846322 | Selexipag: First Global Approval. | Drugs | 2016 Mar |
1 |
| 12 | 27062188 | Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment. | Br J Clin Pharmacol | 2016 Aug |
2 |
| 13 | 27063071 | Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects. | Clin Ther | 2016 May |
1 |
| 14 | 27491673 | A Contemporary Approach to Pulmonary Arterial Hypertension. | Curr Atheroscler Rep | 2016 Sep |
1 |
| 15 | 27895464 | Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy. | Drug Des Devel Ther | 2016 |
1 |
| 16 | 27919660 | A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries. | Eur J Pharmacol | 2017 Jan 15 |
2 |
| 17 | 28277164 | Pharmacokinetics of the selective prostacyclin receptor agonist selexipag in rats, dogs and monkeys. | Xenobiotica | 2018 Feb |
2 |
| 18 | 28399721 | The prostacyclin pathway in pulmonary arterial hypertension: a clinical review. | Expert Rev Respir Med | 2017 Jun |
1 |
| 19 | 28420826 | Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension. | Circ J | 2017 Aug 25 |
3 |
| 20 | 28478717 | Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension. | Ann Pharmacother | 2017 Jun |
1 |
| 21 | 28494686 | Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension. | Expert Opin Drug Saf | 2017 Jun |
1 |
| 22 | 28524738 | Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review. | Expert Rev Clin Pharmacol | 2017 Jul |
2 |
| 23 | 28639119 | A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects. | Eur J Clin Pharmacol | 2017 Sep |
5 |
| 24 | 28639216 | Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag. | Eur J Drug Metab Pharmacokinet | 2018 Feb |
2 |
| 25 | 28715853 | Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects. | Br J Clin Pharmacol | 2017 Dec |
3 |
| 26 | 28737453 | The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag. | Xenobiotica | 2018 Jul |
10 |
| 27 | 28818881 | Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. | Eur Respir J | 2017 Aug |
9 |
| 28 | 29073911 | Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension. | BMC Pulm Med | 2017 Oct 26 |
1 |
| 29 | 29468921 | Cross-species comparison of the metabolism and excretion of selexipag. | Xenobiotica | 2019 Mar |
1 |
| 30 | 29588339 | Selective Prostacyclin Receptor Agonist Selexipag, in Contrast to Prostacyclin Analogs, Does Not Evoke Paradoxical Vasoconstriction of the Rat Femoral Artery. | J Pharmacol Exp Ther | 2018 Jun |
3 |
| 31 | 29720235 | Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts. | Arthritis Res Ther | 2018 May 2 |
2 |
| 32 | 30267780 | Contribution of Human Liver and Intestinal Carboxylesterases to the Hydrolysis of Selexipag In Vitro. | J Pharm Sci | 2019 Feb |
9 |
| 33 | 30526673 | Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA). | Orphanet J Rare Dis | 2018 Dec 10 |
1 |
| 34 | 30671881 | Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol. | Am J Cardiovasc Drugs | 2019 Apr |
1 |
| 35 | 31042010 | Prostacyclin for pulmonary arterial hypertension. | Cochrane Database Syst Rev | 2019 May 1 |
1 |
| 36 | 32110381 | Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension. | Pulm Circ | 2020 Jan-Mar |
1 |
| 37 | 32415684 | Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects. | Br J Clin Pharmacol | 2021 Jan |
3 |
| 38 | 32867545 | An evaluation of selexipag for the treatment of pulmonary hypertension. | Expert Opin Pharmacother | 2021 Jan |
1 |
| 39 | 32879152 | Selexipag for Chronic Thromboembolic Pulmonary Hypertension in Japanese Patients - A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase II Study. | Circ J | 2020 Sep 25 |
1 |
| 40 | 32997809 | Clinical evaluation of drug-drug interactions between the cytochrome P450 substrates selexipag and clopidogrel in Japanese volunteers. | Br J Clin Pharmacol | 2021 Apr |
2 |
| 41 | 33057388 | The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats. | PLoS One | 2020 |
3 |
| 42 | 33526303 | Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE. | J Heart Lung Transplant | 2021 Apr |
1 |
| 43 | 33539988 | Use of the Prostacyclin Receptor Agonist Selexipag in Patients With Pulmonary Arterial Hypertension Associated With Eisenmenger Syndrome. | Can J Cardiol | 2021 Aug |
2 |
| 44 | 33952848 | [Pharmacological characteristics and clinical study results of Selexipag (Uptravi<sup>®</sup> tablets), a selective prostacyclin receptor agonist]. | Nihon Yakurigaku Zasshi | 2021 |
2 |
| 45 | 34727317 | Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. | Adv Ther | 2022 Jan |
1 |
| 46 | 35598975 | Selexipag improves Lipopolysaccharide-induced ARDS on C57BL/6 mice by modulating the cAMP/PKA and cAMP/Epac1 signaling pathways. | Biol Pharm Bull | 2022 May 20 |
1 |